U.S. markets close in 4 hours 30 minutes

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
39.83+0.48 (+1.22%)
As of 11:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close39.35
Bid39.75 x 1200
Ask39.76 x 1000
Day's Range39.31 - 39.84
52 Week Range29.99 - 43.08
Avg. Volume30,371,570
Market Cap222.178B
Beta (5Y Monthly)0.67
PE Ratio (TTM)20.18
EPS (TTM)1.97
Earnings DateJul 26, 2021 - Jul 30, 2021
Forward Dividend & Yield1.56 (3.96%)
Ex-Dividend DateMay 06, 2021
1y Target Est42.46
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    UPDATE 1-Swiss aim to re-open economy, donate AstraZeneca COVID-19 shots

    Switzerland aims to expand its economic re-opening and may donate millions of AstraZeneca COVID-19 vaccine doses to developing countries as the Alpine nation grows increasingly confident it is beating back the pandemic. Health Minister Alain Berset on Wednesday said the country may give 3 million of 5.4 million AstraZeneca doses it has reserved to the COVAX vaccine sharing programme. Switzerland has enough mRNA shots from producers including Pfizer and Moderna to cover 2021 and 2022, Berset said.

  • Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters

    Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters

    According to Reuters, Samsung BioLogics Co Ltd and Pfizer Inc (NYSE: PFE) have denied reports claiming they were working together to produce the COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) in South Korea. The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer/BioNTech vaccine. The report quoted an unnamed high-level government official and said that the plant could make up to 1 billion doses per year, with production starting from August. Samsung BioLogics said in a one-line filing to the stock exchange that the report was "not factual." Pfizer said its current production strategy was centered on its two dedicated supply lines in the U.S. and Europe. "At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine," Pfizer said in a statement. South Korea has secured 192 million doses, enough to vaccinate all 52 million residents twice over. But President Moon Jae-in is under pressure to secure more and faster deliveries of U.S.-made shots as he heads for his first summit with U.S. President Joe Biden next week. Price Action: PFE shares are up 0.23% at $39.44 during the premarket session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaFDA Outlines Plan For Restarting Facility Inspections Halted Due To PandemicUK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.